Pharmicell Co (A005690) Q1 2025 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, fine chemicals).

• Q1 2025 revenue was KRW 27.0 billion, with operating income of KRW 8.4 billion and net income of KRW 8.5 billion.

• Maintains a strong R&D pipeline, including late-stage clinical trials for stem cell therapies targeting liver cirrhosis, erectile dysfunction, and chronic kidney disease.

• No subsidiaries or affiliates as of the reporting date.

Financial highlights

• Revenue for Q1 2025: KRW 27.0 billion, up from KRW 11.0 billion in Q1 2024.

• Operating income: KRW 8.4 billion (Q1 2025) vs. operating loss of KRW 2.0 billion (Q1 2024).

• Net income: KRW 8.5 billion (Q1 2025) vs. net loss of KRW 1.4 billion (Q1 2024).

• Cash and cash equivalents at Q1 2025: KRW 7.0 billion.

• Total assets: KRW 106.0 billion; total equity: KRW 93.7 billion.

Outlook and guidance

• Continued investment in R&D, with multiple clinical trials ongoing and new product launches planned.

• Expansion of production capacity, including new GMP and chemical plants.

• Anticipates growth in both domestic and international markets, especially in stem cell and nucleoside segments.